ZAP Surgical Systems has announced that Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC) in Boulogne, France, has initiated patient treatments with the ZAP-X Gyroscopic Radiosurgery platform. CCPSC is the first in France to offer ZAP-X and is part of the American Hospital of Paris, known for offering the innovative technologies and advanced treatment methods. In this initiation, CCPSC treated three patients on their first day, each with a single brain metastasis.
As a non-invasive and painless treatment for select primary and metastatic brain tumours, stereotactic radiosurgery (SRS) has proven to provide equivalent to superior outcomes compared to costly and potentially debilitating surgeries. SRS is typically delivered in one to five brief outpatient visits and patients often return to normal activity the same day as the procedure.
Dr Bacem Belghith, radiation oncologist at the CCPSC said: “Because of the significant percentage of cancer patients who develop brain metastases, it was imperative we support our radiation oncology program with a dedicated SRS solution such as ZAP-X.”
“As ZAP-X is designed specifically for cranial radiosurgery it allows us to treat the most challenging cases with confidence,” added Dr Alain Allaw, radiation oncologist at the CCPSC. “And unlike multi-purpose radiotherapy devices, ZAP-X provides patients with potentially lower healthy brain exposure to radiation, and thus enables greater flexibility for our clinical team to treat recurring brain metastases patients.”
The ZAP-X system uses unique gyroscopic mobility to direct radio-surgical beams from hundreds of angles to precisely concentrate radiation on the tumour target. This pioneering approach supports the clinical objective of protecting healthy brain tissue and patient cognitive function.
As the first and only vault-free and cobalt-free dedicated SRS delivery system, ZAP-X also eliminates the expense of building costly shielded radiation treatment rooms, and removes the need to maintain, secure and regularly replace live radioactive isotopes.
“As the first centre to retrofit an existing shielded radiotherapy suite, ZAP-X has seamlessly integrated into CCPSC’s busy radiation oncology department and now serves as the centre piece of an elite SRS program,” said Hakan Baraner, ZAP Surgical Senior Vice President for Europe, India, Middle East, and Africa (EIMEA), adding: “ZAP is incredibly honoured to support CCPSC in bringing world-class care to their patients.”
